Savara (SVRA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.15B and a free-cash-flow yield of -8.6%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.0/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Lagging · +0.0% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-39.1%
How far the last close sits under the highest price of the past five years.
Market cap
$1.15B
Trailing P/E
—
Price / book
10.0
Price / sales
—
FCF yield
-8.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.3
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
SVRA earnings
Next report: Mar 12, 2027 (Q4 2026, EPS estimate -$0.17).
Beat the EPS estimate in 0 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 9, 2026
-$0.17
-$0.17
+0.0%
$0
Q2 2026
Aug 11, 2026
-$0.16
-$0.15
-6.7%
$0
Q4 2025
Mar 13, 2026
-$0.13
-$0.12
-8.3%
$0
Q3 2025
Nov 12, 2025
-$0.14
-$0.13
-7.7%
$0
SVRA analyst price target
Median target $10.50 from 9 analysts, ranging $9.00 – $16.00.
Nama's AI scorecard currently rates Savara Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SVRA report earnings?
Savara's next scheduled report is on Mar 12, 2027. Analysts expect EPS of -$0.17.
What is the SVRA price target?
The median analyst price target from 9 analysts is $10.50, with a range of $9.00 – $16.00.
Is SVRA Shariah compliant?
Nama's AAOIFI-style screen reads Savara as Can't Tell. A figure the screen needs is missing, so it can't tell.